<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ja">
	<id>https://bsd.neuroinf.jp/w/index.php?action=history&amp;feed=atom&amp;title=8%CE%B2-VE2</id>
	<title>8β-VE2 - 版の履歴</title>
	<link rel="self" type="application/atom+xml" href="https://bsd.neuroinf.jp/w/index.php?action=history&amp;feed=atom&amp;title=8%CE%B2-VE2"/>
	<link rel="alternate" type="text/html" href="https://bsd.neuroinf.jp/w/index.php?title=8%CE%B2-VE2&amp;action=history"/>
	<updated>2026-04-12T10:58:09Z</updated>
	<subtitle>このウィキのこのページに関する変更履歴</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://bsd.neuroinf.jp/w/index.php?title=8%CE%B2-VE2&amp;diff=49746&amp;oldid=prev</id>
		<title>WikiSysop: 1版 をインポートしました</title>
		<link rel="alternate" type="text/html" href="https://bsd.neuroinf.jp/w/index.php?title=8%CE%B2-VE2&amp;diff=49746&amp;oldid=prev"/>
		<updated>2025-03-18T10:27:38Z</updated>

		<summary type="html">&lt;p&gt;1版 をインポートしました&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;ja&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← 古い版&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;2025年3月18日 (火) 19:27時点における版&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;4&quot; class=&quot;diff-notice&quot; lang=&quot;ja&quot;&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;(相違点なし)&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;!-- diff cache key wiki-mw_:diff:1.41:old-49745:rev-49746 --&gt;
&lt;/table&gt;</summary>
		<author><name>WikiSysop</name></author>
	</entry>
	<entry>
		<id>https://bsd.neuroinf.jp/w/index.php?title=8%CE%B2-VE2&amp;diff=49745&amp;oldid=prev</id>
		<title>bsd&gt;Citation bot: Added doi-access. | Use this bot. Report bugs. | Suggested by Headbomb | #UCB_toolbar</title>
		<link rel="alternate" type="text/html" href="https://bsd.neuroinf.jp/w/index.php?title=8%CE%B2-VE2&amp;diff=49745&amp;oldid=prev"/>
		<updated>2024-03-28T06:27:58Z</updated>

		<summary type="html">&lt;p&gt;Added doi-access. | &lt;a href=&quot;https://en.wikipedia.org/wiki/WP:UCB&quot; class=&quot;extiw&quot; title=&quot;en:WP:UCB&quot;&gt;Use this bot&lt;/a&gt;. &lt;a href=&quot;https://en.wikipedia.org/wiki/WP:DBUG&quot; class=&quot;extiw&quot; title=&quot;en:WP:DBUG&quot;&gt;Report bugs&lt;/a&gt;. | Suggested by Headbomb | #UCB_toolbar&lt;/p&gt;
&lt;p&gt;&lt;b&gt;新規ページ&lt;/b&gt;&lt;/p&gt;&lt;div&gt;{{Short description|Chemical compound}}&lt;br /&gt;
{{Drugbox&lt;br /&gt;
| Verifiedfields = &lt;br /&gt;
| Watchedfields = &lt;br /&gt;
| verifiedrevid = &lt;br /&gt;
| IUPAC_name = 8β-Vinylestra-1,3,5(10)-triene-3,17β-diol&lt;br /&gt;
| image = 8-vinylestradiol_structure.png&lt;br /&gt;
| width = 250px&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Clinical data--&amp;gt;&lt;br /&gt;
| tradename = &lt;br /&gt;
| pregnancy_AU = &amp;lt;!-- A / B1 / B2 / B3 / C / D / X --&amp;gt;&lt;br /&gt;
| pregnancy_US = &amp;lt;!-- A / B / C / D / X --&amp;gt;&lt;br /&gt;
| pregnancy_category = &lt;br /&gt;
| legal_AU = &amp;lt;!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --&amp;gt;&lt;br /&gt;
| legal_CA = &lt;br /&gt;
| legal_UK = &lt;br /&gt;
| legal_US = &lt;br /&gt;
| legal_status = &lt;br /&gt;
| routes_of_administration =&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Pharmacokinetic data--&amp;gt;&lt;br /&gt;
| bioavailability = &lt;br /&gt;
| protein_bound = &lt;br /&gt;
| metabolism = &lt;br /&gt;
| elimination_half-life = &lt;br /&gt;
| excretion =&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!-- Identifiers --&amp;gt;&lt;br /&gt;
| CAS_number_Ref = {{cascite|correct|CAS}}&lt;br /&gt;
| CAS_number = 367929-02-0&lt;br /&gt;
| CAS_supplemental = &lt;br /&gt;
| ATC_prefix = &lt;br /&gt;
| ATC_suffix = &lt;br /&gt;
| ATC_supplemental = &lt;br /&gt;
| PubChem = &lt;br /&gt;
| IUPHAR_ligand = &lt;br /&gt;
| DrugBank_Ref = &lt;br /&gt;
| DrugBank = &lt;br /&gt;
| ChemSpiderID_Ref = &lt;br /&gt;
| ChemSpiderID = 8007830&lt;br /&gt;
| UNII_Ref = {{fdacite|correct|FDA}}&lt;br /&gt;
| UNII = D5KU4JGS7Y&lt;br /&gt;
| KEGG = &lt;br /&gt;
| ChEBI = &lt;br /&gt;
| ChEMBL =&lt;br /&gt;
| synonyms = 8β-Vinylestradiol; 8β-Vinylestra-1,3,5(10)-triene-3β,17β-diol&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Chemical data--&amp;gt;&lt;br /&gt;
| C=20 | H=26 | O=2&lt;br /&gt;
| SMILES = C=C[C@@]12CCC3=CC(O)=CC=C3[C@@]1([H])CC[C@]4([C@@]2([H])CC[C@]4([H])O)C&lt;br /&gt;
| StdInChI_Ref = &lt;br /&gt;
| StdInChI = 1S/C20H26O2/c1-3-20-11-8-13-12-14(21)4-5-15(13)16(20)9-10-19(2)17(20)6-7-18(19)22/h3-5,12,16-18,21-22H,1,6-11H2,2H3/t16-,17-,18+,19+,20-/m1/s1&lt;br /&gt;
| StdInChIKey_Ref = &lt;br /&gt;
| StdInChIKey = NMCRWZRLOOYKTG-SWBPCFCJSA-N&lt;br /&gt;
}}&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;8β-VE2&amp;#039;&amp;#039;&amp;#039;, or &amp;#039;&amp;#039;&amp;#039;8β-vinylestradiol&amp;#039;&amp;#039;&amp;#039;, also known as &amp;#039;&amp;#039;&amp;#039;8β-vinylestra-1,3,5(10)-triene-3β,17β-diol&amp;#039;&amp;#039;&amp;#039;, is a [[synthetic compound|synthetic]] [[estrogen (medication)|estrogen]] featuring an [[estradiol (medication)|estradiol]] core.&amp;lt;ref name=&amp;quot;Shaw2009&amp;quot;&amp;gt;{{cite book | vauthors = Pakdel F, Kah O, Jégou B | chapter = Mechanisms of action of particular endocrine-disrupting chemicals | veditors = Shaw I |title=Endocrine-Disrupting Chemicals in Food| chapter-url = https://books.google.com/books?id=x6ejAgAAQBAJ&amp;amp;pg=PA550|date=31 March 2009|publisher=Elsevier|isbn=978-1-84569-574-3|pages=550–}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid15037755&amp;quot;&amp;gt;{{cite journal | vauthors = Hegele-Hartung C, Siebel P, Peters O, Kosemund D, Müller G, Hillisch A, Walter A, Kraetzschmar J, Fritzemeier KH | display-authors = 6 | title = Impact of isotype-selective estrogen receptor agonists on ovarian function | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 101 | issue = 14 | pages = 5129–5134 | date = April 2004 | pmid = 15037755 | pmc = 387385 | doi = 10.1073/pnas.0306720101 | doi-access = free | bibcode = 2004PNAS..101.5129H }}&amp;lt;/ref&amp;gt; It is a highly [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[agonist]] of the [[ERβ]] that is used in [[scientific research]] to study the function of the ERβ.&amp;lt;ref name=&amp;quot;Shaw2009&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;pmid15037755&amp;quot; /&amp;gt; It has 190-fold higher [[potency (pharmacology)|potency]] in [[transactivation]] [[bioassay|assay]]s of the ERβ relative to the [[ERα]] and 93- (rat) and 180-fold (human) preference in [[binding affinity]] for the ERβ over the ERα.&amp;lt;ref name=&amp;quot;pmid15037755&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
In rodents, 8β-VE2 stimulates follicular growth and to a comparable extent as estradiol, whereas the highly ERα-selective agonist [[16α-LE2]] has no effect on [[ovarian follicle]] development, indicating that the ERβ and not the ERα is involved in the effects of estrogen on ovarian follicles.&amp;lt;ref name=&amp;quot;pmid15037755&amp;quot; /&amp;gt;&amp;lt;ref name=&amp;quot;PlantZeleznik2014&amp;quot;&amp;gt;{{cite book | vauthors = Binder K, Winuthayanon W, Hewitt SC, Couse JF, Korach KS | chapter = Steroid Receptors in the Uterus and Ovary| veditors = Plant TM, Zeleznik AJ |title=Knobil and Neill&amp;#039;s Physiology of Reproduction| chapter-url = https://books.google.com/books?id=I1ACBAAAQBAJ&amp;amp;pg=PA1150|date=15 November 2014|publisher=Academic Press|isbn=978-0-12-397769-4|pages=1150–}}&amp;lt;/ref&amp;gt; In contrast, 16α-LE2 stimulates [[uterus|uterine]] weight, whereas 8β-VE2 has no effect, indicating that the ERα and not the ERβ is involved in the effects of estrogen on the uterus.&amp;lt;ref name=&amp;quot;pmid15037755&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Research has determined through experimental [[animal testing on rodents|rodent studies]] with estradiol, 16α-LE2, and 8β-VE2 that the positive, protective effects of estrogens on [[bone formation]] [[bone resorption|resorption]] and [[bone mineral density]] are mediated via the ERα, whereas the ERβ does not appear to be involved.&amp;lt;ref name=&amp;quot;pmid18433985&amp;quot;&amp;gt;{{cite journal | vauthors = Hertrampf T, Schleipen B, Velders M, Laudenbach U, Fritzemeier KH, Diel P | title = Estrogen receptor subtype-specific effects on markers of bone homeostasis | journal = Molecular and Cellular Endocrinology | volume = 291 | issue = 1–2 | pages = 104–108 | date = September 2008 | pmid = 18433985 | doi = 10.1016/j.mce.2008.03.003 | s2cid = 1774519 | url = https://hal.archives-ouvertes.fr/hal-00532015/file/PEER_stage2_10.1016%252Fj.mce.2008.03.003.pdf }}&amp;lt;/ref&amp;gt; On the other hand, while both ERα and ERβ are expressed in [[skeletal muscle]], it was found that ERβ is the predominant ER subtype that is responsible for estrogen stimulation of skeletal muscle growth and regeneration.&amp;lt;ref name=&amp;quot;pmid22278942&amp;quot;&amp;gt;{{cite journal | vauthors = Velders M, Schleipen B, Fritzemeier KH, Zierau O, Diel P | title = Selective estrogen receptor-β activation stimulates skeletal muscle growth and regeneration | journal = FASEB Journal | volume = 26 | issue = 5 | pages = 1909–1920 | date = May 2012 | pmid = 22278942 | doi = 10.1096/fj.11-194779 | doi-access = free | s2cid = 39692168 }}&amp;lt;/ref&amp;gt; Moreover, similarly to [[testosterone]], 8β-VE2 has [[anabolic]] effects in skeletal muscle and significantly increases muscle mass as well as produces [[muscle hypertrophy]] in rats.&amp;lt;ref name=&amp;quot;pmid22278942&amp;quot; /&amp;gt; In contrast to testosterone however, 8β-VE2 shows no [[androgenic]] effects.&amp;lt;ref name=&amp;quot;pmid22278942&amp;quot; /&amp;gt; The effects of 8β-VE2 and ERβ may be mediated, in part, by local stimulation of [[insulin-like growth factor 1]] (IGF-1)-induced [[myogenesis|myogenic]] [[protein synthesis]], as 8β-VE2 has been found to strongly induce expression of IGF-1 in the rat [[levator ani]] muscle.&amp;lt;ref name=&amp;quot;pmid22278942&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== See also ==&lt;br /&gt;
* [[Diarylpropionitrile]]&lt;br /&gt;
* [[ERB-196]]&lt;br /&gt;
* [[Erteberel]]&lt;br /&gt;
* [[FERb 033]]&lt;br /&gt;
* [[Prinaberel]]&lt;br /&gt;
* [[WAY-166818]]&lt;br /&gt;
* [[WAY-200070]]&lt;br /&gt;
* [[WAY-214156]]&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
{{Reflist}}&lt;br /&gt;
&lt;br /&gt;
{{Estrogen receptor modulators}}&lt;br /&gt;
&lt;br /&gt;
[[Category:Estranes]]&lt;br /&gt;
[[Category:Selective ERβ agonists]]&lt;br /&gt;
[[Category:Synthetic estrogens]]&lt;br /&gt;
[[Category:Vinyl compounds]]&lt;/div&gt;</summary>
		<author><name>bsd&gt;Citation bot</name></author>
	</entry>
</feed>